疾病预防控制中心42基因突变作为免疫检查点抑制剂治疗的反应生物标志物
Kun Wang1,2,3, Yingying Zhang1,2,3, Zhaoming Su4
1School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Cancer medicine
|January 10, 2025
概括
疾病预防控制中心42基因组中的突变可能预测患者对免疫检查点抑制剂 (ICI) 的反应. 这一发现可能会导致更好的患者选择和组合疗法,以改善癌症治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 免疫检查点抑制剂 (ICI) 是有前途的,但缺乏对非响应者的预测生物标志物.
- CDC42信号通路与瘤生长有关,这表明它在治疗反应中起作用.
研究的目的:
- 调查CDC42基因组突变作为ICI治疗反应的预测生物标志物.
- 探索与ICI结合针对CDC42的机制基础和治疗潜力.
主要方法:
- 对CDC42基因组突变的综合发现数据集 (七个ICI队列) 和验证数据集 (两个ICI队列) 的分析.
- 探索癌症基因组图谱 (TCGA) 数据库以获得机械洞察力.
- 在临床前模型中,评估将CDC42抑制剂与ICI结合在一起.
主要成果:
- 在ICI治疗患者中,CDC42基因组突变与改善的整体存活率和无进展存活率相关.
- 免疫反应景观分析支持CDC42基因组作为预测生物标志物的作用.
- 与CDC42抑制剂 (ML141) 和抗PD-1阻断的组合疗法在体内证明了添加性瘤生长减少.
结论:
- 在CDC42基因组中的突变代表了预测ICI治疗临床反应的潜在新生物标志物.
- 针对CDC42与ICI结合,可能为癌症患者提供更有效的治疗策略.
相关概念视频
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:27Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472